Orphan Drug Designation

Orphan Drug Designation (ODD) is a status granted by the EMA or FDA to medicines intended for rare diseases.

It provides regulatory and financial incentives such as market exclusivity, fee reductions, and scientific guidance.

The scheme encourages the development of treatments for conditions with high unmet medical needs, supporting innovation in orphan drug research.